扶桑薬品工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/06/20 | 2,021 | 2,038 | 2,007 | 2,031 | -4 | -0.2% | 9,700 |
2023/06/19 | 2,045 | 2,045 | 2,022 | 2,035 | +17 | +0.8% | 7,000 |
2023/06/16 | 2,009 | 2,021 | 1,996 | 2,018 | +9 | +0.4% | 13,000 |
2023/06/15 | 2,020 | 2,034 | 2,009 | 2,009 | -23 | -1.1% | 7,800 |
2023/06/14 | 1,986 | 2,037 | 1,986 | 2,032 | +26 | +1.3% | 12,100 |
2023/06/13 | 1,973 | 2,007 | 1,973 | 2,006 | +25 | +1.3% | 7,500 |
2023/06/12 | 1,986 | 1,995 | 1,981 | 1,981 | +15 | +0.8% | 1,900 |
2023/06/09 | 1,978 | 1,985 | 1,966 | 1,966 | +14 | +0.7% | 8,600 |
2023/06/08 | 1,960 | 1,975 | 1,951 | 1,952 | -9 | -0.5% | 8,000 |
2023/06/07 | 1,994 | 1,994 | 1,960 | 1,961 | -24 | -1.2% | 7,900 |
2023/06/06 | 1,966 | 1,993 | 1,966 | 1,985 | ±0 | ±0% | 2,000 |
2023/06/05 | 1,976 | 2,002 | 1,976 | 1,985 | +34 | +1.7% | 7,700 |
2023/06/02 | 1,933 | 1,962 | 1,933 | 1,951 | +13 | +0.7% | 3,900 |
2023/06/01 | 1,922 | 1,954 | 1,922 | 1,938 | +16 | +0.8% | 6,700 |
2023/05/31 | 1,952 | 1,989 | 1,922 | 1,922 | -53 | -2.7% | 19,000 |
2023/05/30 | 1,990 | 2,000 | 1,975 | 1,975 | -30 | -1.5% | 7,000 |
2023/05/29 | 1,994 | 2,016 | 1,985 | 2,005 | -9 | -0.4% | 9,500 |
2023/05/26 | 2,022 | 2,038 | 2,000 | 2,014 | -14 | -0.7% | 5,900 |
2023/05/25 | 2,054 | 2,066 | 2,028 | 2,028 | -25 | -1.2% | 7,000 |
2023/05/24 | 2,044 | 2,053 | 2,044 | 2,053 | +13 | +0.6% | 1,000 |
2023/05/23 | 2,049 | 2,061 | 2,026 | 2,040 | -13 | -0.6% | 9,000 |
2023/05/22 | 2,050 | 2,055 | 2,040 | 2,053 | +13 | +0.6% | 8,500 |
2023/05/19 | 2,023 | 2,042 | 2,002 | 2,040 | +7 | +0.3% | 5,500 |
2023/05/18 | 2,049 | 2,049 | 2,024 | 2,033 | -6 | -0.3% | 5,700 |
2023/05/17 | 2,038 | 2,045 | 2,037 | 2,039 | +1 | ±0% | 3,200 |
2023/05/16 | 2,039 | 2,055 | 2,027 | 2,038 | -12 | -0.6% | 4,100 |
2023/05/15 | 2,029 | 2,050 | 2,029 | 2,050 | +21 | +1% | 3,200 |
2023/05/12 | 2,013 | 2,029 | 1,989 | 2,029 | +32 | +1.6% | 6,500 |
2023/05/11 | 2,039 | 2,039 | 1,997 | 1,997 | -42 | -2.1% | 5,400 |
2023/05/10 | 2,063 | 2,063 | 2,026 | 2,039 | -18 | -0.9% | 8,400 |
2023/05/09 | 2,027 | 2,063 | 2,027 | 2,057 | +30 | +1.5% | 7,900 |
2023/05/08 | 2,024 | 2,060 | 2,024 | 2,027 | -11 | -0.5% | 7,900 |
2023/05/02 | 2,046 | 2,049 | 2,024 | 2,038 | -8 | -0.4% | 4,000 |
2023/05/01 | 2,057 | 2,059 | 2,034 | 2,046 | -2 | -0.1% | 6,300 |
2023/04/28 | 2,010 | 2,048 | 2,010 | 2,048 | +40 | +2% | 4,700 |
2023/04/27 | 2,060 | 2,060 | 2,008 | 2,008 | -41 | -2% | 11,600 |
2023/04/26 | 2,032 | 2,049 | 2,021 | 2,049 | +17 | +0.8% | 2,500 |
2023/04/25 | 2,062 | 2,063 | 2,026 | 2,032 | -11 | -0.5% | 5,700 |
2023/04/24 | 2,050 | 2,050 | 2,033 | 2,043 | -2 | -0.1% | 2,000 |
2023/04/21 | 2,050 | 2,050 | 2,028 | 2,045 | -2 | -0.1% | 3,100 |
2023/04/20 | 2,036 | 2,048 | 2,012 | 2,047 | -14 | -0.7% | 7,800 |
2023/04/19 | 2,030 | 2,061 | 2,030 | 2,061 | +11 | +0.5% | 6,000 |
2023/04/18 | 2,021 | 2,050 | 2,007 | 2,050 | +44 | +2.2% | 5,000 |
2023/04/17 | 2,027 | 2,027 | 1,997 | 2,006 | -21 | -1% | 4,400 |
2023/04/14 | 2,020 | 2,027 | 2,017 | 2,027 | +7 | +0.3% | 4,200 |
2023/04/13 | 2,011 | 2,020 | 2,000 | 2,020 | +18 | +0.9% | 3,900 |
2023/04/12 | 1,998 | 2,011 | 1,992 | 2,002 | +4 | +0.2% | 4,000 |
2023/04/11 | 1,969 | 1,998 | 1,968 | 1,998 | +29 | +1.5% | 5,800 |
2023/04/10 | 1,964 | 1,970 | 1,954 | 1,969 | +5 | +0.3% | 3,300 |
2023/04/07 | 1,972 | 1,976 | 1,941 | 1,964 | +6 | +0.3% | 6,900 |
451~
500
件表示中 / 3685件
類似銘柄と比較する
現在ご覧いただいている「扶桑薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
扶桑薬 | 230,500円 | +8.3% | +98.1% | 3.56% | 7.57倍 | 0.52倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア5割。後発薬や製造受託も展開 |
ヘリオス | 27,800円 | +150.0% | - | 0.00% | - | 13.67倍 |
|
iPS細胞、体性幹細胞を活用する再生医薬品バイオベンチャー。住友ファーマと共同開発も |
アンジェス | 7,000円 | +110.0% | - | 0.00% | - | 11.38倍 |
|
大阪大医学部、森下竜一教授創業の創薬ベンチャー。遺伝子治療薬を核に核酸医薬など開発多彩 |
ステムリム | 33,100円 | - | - | 0.00% | - | 3.05倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
CANBAS | 100,000円 | - | - | 0.00% | - | 6.40倍 |
|
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索 |
市場注目の銘柄
チャート関連のコラム